LONDON, July 14, 2026. ProMIS Neurosciences presented what the company described as the first human evidence of dose-dependent reduction in toxic amyloid-beta oligomers, a key driver of neuronal damage in Alzheimer’s disease, at the Alzheimer’s Association International Conference here on Tuesday.

The data, drawn from an early clinical study of the company’s lead candidate PMN310, showed that patients receiving the antibody had measurable reductions in detectable amyloid-beta oligomers in cerebrospinal fluid at both three days and 29 days after dosing, with the size of the reduction tracking the dose administered. PMN310 is designed to selectively target the toxic oligomer form of amyloid-beta while sparing the plaque form, a distinction the company argues could translate into a cleaner safety profile than earlier plaque-clearing antibodies.

The presentation came on the third full day of AAIC 2026, which is running in London and online through July 16 and has drawn thousands of dementia researchers, clinicians and drug developers. Biogen also presented findings on the same day from a mid-stage study of diranersen, an antisense candidate targeting tau protein, adding to a growing body of clinical data this week aimed at moving Alzheimer’s treatment beyond amyloid plaque clearance alone.

Investors and researchers have watched the oligomer-targeting approach closely since a growing body of preclinical and clinical evidence has suggested that soluble oligomers, rather than the insoluble plaques that dominated the first generation of approved Alzheimer’s antibodies, may correlate more directly with cognitive decline. A therapy that can clear oligomers with a favorable safety profile, including a lower rate of brain swelling and microhemorrhage than seen with earlier approved antibodies, would address one of the most persistent limitations of the current treatment class.

Analysts covering the space noted that early-stage biomarker data, while encouraging, still needs to be followed by evidence of a meaningful effect on cognitive and functional outcomes before it can support a regulatory filing. ProMIS has not yet disclosed a timeline for advancing PMN310 into a pivotal study, though the company indicated further data updates are expected later this year.

The dual presentations from ProMIS and Biogen underscore how crowded and fast-moving the post-amyloid Alzheimer’s pipeline has become, with multiple companies now pursuing tau, oligomer-specific, and inflammation-targeted mechanisms in parallel rather than betting on a single approach to slowing the disease.